KNBIF (Kane Biotech) Change In Receivables: $0.13 Mil (TTM As of Mar. 2026)


What is Kane Biotech Change In Receivables?

Kane Biotech KNBIF -4.79% Change In Receivables is $0.13 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Kane Biotech's change in receivables for the quarter that ended in Mar. 2026 was $0.01 Mil. It means Kane Biotech's Accounts Receivable declined by $0.01 Mil from Dec. 2025 to Mar. 2026 .

Kane Biotech's change in receivables for the fiscal year that ended in Dec. 2025 was $0.04 Mil. It means Kane Biotech's Accounts Receivable declined by $0.04 Mil from Dec. 2024 to Dec. 2025 .

Kane Biotech's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.02 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Kane Biotech's Days Sales Outstanding for the three months ended in Mar. 2026 was 61.81.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kane Biotech's liquidation value for the three months ended in Mar. 2026 was $-1.88 Mil.

Kane Biotech  (OTCPK:KNBIF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kane Biotech's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.021/0.031*91
=61.81

2. In Ben Graham's calculation of liquidation value, Kane Biotech's accounts receivable are only considered to be worth 75% of book value:

Kane Biotech's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.288-2.353+0.75 * 0.021+0.5 * 0.348
=-1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Change In Receivables Related Terms

Kane Biotech Change In Receivables Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Change In Receivables Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.21 0.00 0.01 0.04

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 0.05 0.01 0.07 0.01

Kane Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.13 Mil mean?
Kane Biotech (KNBIF) has a Change In Receivables of $0.13 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Kane Biotech and its competitors.
Is Kane Biotech's Change In Receivables too high?
Kane Biotech's current Change In Receivables is $0.13 Mil.
How does Kane Biotech's Change In Receivables compare to VRTX and REGN?
Kane Biotech's Change In Receivables of $0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Kane Biotech and its competitors. Kane Biotech's current Change In Receivables is $0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Change In Receivables of $0.13 Mil. The current Change In Receivables is $0.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Change In Receivables is $0.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.